Clinical and socioeconomic relevance of overactive bladder

Urology

Volumn 63, Issue 3 SUPPL. 1, 2004, Pages 42-44

  Debruyne, Frans M J ^a   Heesakkers, John P F A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; SOLIFENACIN;

COMORBIDITY; CONFERENCE PAPER; DEVELOPING COUNTRY; ECONOMIC ASPECT; HEALTH CARE FINANCING; HUMAN; MEDICAL ASSESSMENT; NOCTURNAL ENURESIS; NURSING HOME; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SOCIOECONOMICS; STRESS INCONTINENCE; TENSION FREE VAGINAL TAPE; URGE INCONTINENCE; URINARY FREQUENCY; URINE INCONTINENCE;

COST OF ILLNESS; HUMANS; URINARY INCONTINENCE;

EID: 1542268289     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.12.001     Document Type: Conference Paper

References (13)

1. Kelleher C.J., Reese P.R., Pleil A.M., et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 8:2002;S608-S615.
2. Wagner T.H., Hu T.W. Economic costs of urinary incontinence in 1995. Urology. 51:1998;355-361.
3. Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178, 2002.
4. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87:2001;760-766.
5. Wein A.J., Rovner E.S. Definition and epidemiology of overactive bladder. Urology. 60:(suppl 5A):2002;7-12.
6. Nitti V. Clinical impact of overactive bladder. Rev Urol. 4:(suppl 2):2002;S2-S6.
7. Wilson L., Brown J.S., Shin G.P., et al. Annual direct cost of urinary incontinence. Obstet Gynecol. 98:2001;398-406.
8. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and impact of overactive bladder in the United States. World J Urol. 20:2003;327-336.
9. Greenberg P.E., Stiglin L.E., Finkelstein S.N., et al. Depression a neglected major illness. J Clin Psychiatry. 54:1993;419-424.
10. National Institute on Aging/National Institutes of Health: 2000 Progress Report on Alzheimer's Disease. Taking the Next Steps. Bethesda, MD: US Department of Health and Human Services Public Health Service, National Institutes of Health, National Institute on Aging; 2000. NIH Publication No. 00-4859.
11. Hu T.-W., Wagner T.H. Economic considerations in overactive bladder. Am J Manag Care. 6:2000;S591-S598.
12. Hu T.-W., Moore K., Subak L., et al. Economics of incontinence. Abrams P., Cardozo L., Khoury S., et al. Incontinence. 2nd International Consultation on Incontinence. 2nd ed. 2002;987-1043 Health Publication Ltd, Plymouth, UK.
13. Kelleher C.J., Cardoza L.D., Khullar V., et al. A medium term analysis of subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 104:1997;988-993.